Feasibility analysis of pharmacy practice based on the evidence-based pharmacy model in the treatment of patients with severe pneumonia

Abstract

Objective: To investigate the application of pharmacy practice based on the evidence‐based pharmacy (EBP) model in the anti‐infective treatment of patients with severe pneumonia.

Methodology: This was a retrospective study. A total of 200 patients diagnosed with severe pneumonia caused by multidrug‐resistant Gram‐negative bacilli(MDR‐GNB) and admitted to Baoding No.1 Central Hospital from April 2023 to March 2024 were randomly assigned to a control group(received conventional anti‐infective treatment) and an experimental group(in addition to the conventional treatment, received pharmacy practice interventions based on the EBP model implemented by clinical pharmacists), with one hundred cases in each group..The two groups were compared in terms of antimicrobial drug use intensity, pre‐antibiotic microbiological testing rates, clinical efficacy, adverse reaction rates, and irrational drug use.

Results: The antimicrobial drug use intensity in the experimental group was significantly lower than that in the control group (P< 0.05), while the pre‐antibiotic microbiological testing rate was significantly higher (P< 0.05). The antimicrobial drug costs and anti‐infective treatment duration in the experimental group were lower than those in the control group (P< 0.05, respectively). The bacterial eradication and overall response in the experimental group were significantly higher than those in the control group (P< 0.05, respectively). Furthermore, adverse reaction and irrational drug use rates were significantly lower in the experimental group compared to the control group (P< 0.05, respectively).

Conclusion: EBP model‐based pharmacy practice may assist physicians in optimizing anti‐infective treatment regimens for patients with severe pneumonia caused by MDR‐GNB, improving treatment outcomes and medication safety while effectively enhancing patient prognosis.